Target Dry AMD
Two consecutive projects have been funded by the Swiss National Science Foundation (SNSF grants no. 160195 and no. 189341) to develop a cell-based non-viral gene therapy to treat dry AMD similarly to the TargetAMD 1.0 approach for wet AMD.
Within the first project, we developed a disease model for dry AMD applying an immunisation with a factor that has been found in eyes of dry AMD patients (carboxyethyl pyrrole). The collaboration with Prof. L. Scapozza, UNIGE, Switzerland, allowed the customized in-house production of this immunogen.
Prof. Z. Ivics, Paul-Ehrlich Institute, Germany, was already in the TargetAMD 1.0 project responsible for the integration profile analysis and thus, for the determination of a crucial safety parameter of our product. He will perform the same analyses in “Target Dry AMD”.